MedTrace Logo

Intravenous Autologous Mesenchymal Stem Cells Transplantation to Treat Middle Cerebral Artery Infarct

NCT01461720 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-04-01

No results posted yet for this study

Summary

This study aims to determine the efficacy of intravenous transplantation of autologous bone marrow-derived mesenchymal stem cells in patients with acute middle cerebral artery infarct.

Conditions

  • Middle Cerebral Artery Infarction

Interventions

OTHER

Standard medical care

Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment.

BIOLOGICAL

Autologous bone marrow-derived mesenchymal stem cells

Single intravenous infusion of autologous bone marrow-derived mesenchymal stem cells concurrently with standard medical care.

Sponsors & Collaborators

  • Cytopeutics Sdn. Bhd.

    collaborator INDUSTRY

  • National University of Malaysia

    lead OTHER

Principal Investigators

  • Norlinah Mohamed Ibrahim, MD · UKM Medical Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2015-12-31
Completion
2016-03-31

Countries

  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01461720 on ClinicalTrials.gov